Delivery Order W81XWH15D0037-0002
Award Date
3/22/17
Potential Completion Date
7/31/22
Potential Value
$24M
Federal Agency
Defense Health Agency
Awardee
Dynport Vaccine Company LLC
Ultimate Awardee
General Dynamics Corp
NAICS Category
541712 - Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Australia
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
2
Legislative Mandate
Service Contract Act
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a cost-plus-fixed-fee delivery order awarded by the Medical Command (MEDCOM) of the U.S. Army to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corporation. The $1,685,156.08 contract is for the Phase 2 clinical trial of the Comprehensive Preventive and Preparedness (CPP) program, which develops medical countermeasures for infectious diseases. The contract is part of Dynport's existing $30 million Preclinical Services for Biopharmaceutical Product Development indefinite...
This is a $2,265,501.00 delivery order contract awarded to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corporation, by the National Institute of Allergy and Infectious Diseases (NIAID) under the Early Phase Clinical Trial Units (EPCTU) IDIQ contract vehicle. The contract is for cost plus fixed fee services to support early phase clinical trials, with a period of performance through July 15, 2025. The contract does not have a set-aside designation. Dynport Vaccine Company has...
This is a federal contract award with a potential value of $139,426.00, issued by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corp. The contract is a Delivery Order under the "Therapeutics Against Infectious Diseases Phase 1" master IDIQ contract. The award is for a PHASE 1 CLINICAL TRIAL UNIT FOR THERAPEUTICS AGAINST...
This is a $3,860,186.71 cost-plus-fixed-fee task order awarded to Dynport Vaccine Company LLC (DVC), a subsidiary of General Dynamics Corporation, by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services. The task order is for Phase 1 clinical trials of therapeutics against infectious diseases and was issued under the Therapeutics Against Infectious Diseases Phase 1 indefinite-delivery, indefinite-quantity...
This is a delivery order under a larger Therapeutics Against Infectious Diseases Phase 1 indefinite delivery/indefinite quantity (IDIQ) contract, awarded by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the U.S. Department of Health and Human Services (HHS). The $117,283 order provides base task funding to the prime contractor, Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corporation, for a Phase 1 clinical trial unit supporting the...
This is a delivery order awarded to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corporation, by the Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases. The $129,670.00 award is part of the Therapeutics Against Infectious Diseases Phase 1 contract vehicle, a multi-year indefinite delivery, indefinite quantity (IDIQ) contract that funds early-stage clinical trials of candidate therapeutics and vaccines. The...
This is a cost-plus-fixed-fee definitive contract awarded by the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corp. The $258,064,432.13 contract is for program reporting and technical services in support of the development and delivery of an FDA-licensed human plasma-derived butyrylcholinesterase (HuBChE) product. The award does not have a set-aside designation. Dynport Vaccine Company...
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corp. The $222,661 award is a delivery order under the Therapeutics Against Infectious Diseases Phase 1 IDIQ contract, which funds Phase 1 clinical trials for therapeutics against infectious diseases. The contract does not have a set-aside designation. This order is for Dynport to conduct Phase 1...
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services. The $99,299 cost-plus-fixed-fee delivery order was placed under the Therapeutics Against Infectious Diseases Phase 1 IDIQ contract, which funds Phase I clinical trials for therapeutic products targeting infectious diseases. The prime contractor is Dynport Vaccine Company LLC, a subsidiary of General Dynamics...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $1.2 million delivery order contract to Dynport Vaccine Company LLC DVC Segment Division for the evaluation of cell lines producing a monoclonal antibody, and production and characterization of a cGMP master cell bank. Dynport Vaccine Company LLC DVC Segment Division, a subsidiary of General Dynamics Corp., will perform this work under its Preclinical Services...